Compare IMCC & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCC | BBLG |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0M | 1.2M |
| IPO Year | 2019 | 2014 |
| Metric | IMCC | BBLG |
|---|---|---|
| Price | $2.39 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 910.6K | 193.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $63.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.54 |
| 52 Week High | $4.15 | $2.89 |
| Indicator | IMCC | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 77.15 | 25.17 |
| Support Level | $0.23 | N/A |
| Resistance Level | $4.15 | $1.35 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | 0.30 | 0.01 |
| Stochastic Oscillator | 74.17 | 11.42 |
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.